The synthesis and the anticonvulsant activity screening of new 5-substituted 2-imino-4-thiazolidinone derivatives




4-thiazolidinones, Dimroth reaction, Knoevenagel reaction, antiepileptic drugs, epilepsy, anticonvulsant activity


Aim. To synthesize 5-ene-4-thiazolidinones containing heterocyclic rings in the molecule as potential anticonvulsants, and screen their anticonvulsant activity on a model of pentylenetetrazole (PTZ) seizures.
Results and discussion. A straightforward and convenient synthesis of novel 5-ene-derivatives of thiazol/oxazole-bearing 4-thiazolidinones as possible anticonvulsant agents was performed. Compounds were characterized using methods of spectral analysis (1H NMR and LC-MS). 5-Chloro-3-methyl-1-phenyl-1H-pyrazole-4-carbaldehyde underwent the aminolysis on a chlorine atom by a molecule of monoethanolamine (MEA) in the Knoevenagel reaction with thiazole/oxazole-bearing 4-thiazolidinones. The preliminary screening of the anticonvulsant activity was performed for the compounds synthesized on the model of PTZ-induced seizures, and active derivatives were identified.
Experimental part. Commercially available 2-aminothiazole and 5-methylisoxazol-3-amine were used as starting compounds for the synthesis of 2-chloro-N-(hetaryl)acetamides. The latter were transformed into thiazole/oxazole-bearing 4-thiazolidinones by the treatment with ammonium isothiocyanate. Modification at C5 position of the heterocycles synthesized was performed by the Knoevenagel reaction with aromatic/heteroaromatic aldehydes and MEA as a catalyst (either equimolar or 0.1 mol% amount) in the ethanol medium. The structure of novel derivatives was confirmed by 1H NMR and LC-MS spectra. The anticonvulsant activity of all derivatives synthesized was studied in vivo on the model of PTZ-induced seizures. Latency of the seizures, the number of clonic-tonic seizures in one mouse, the percent of animals with clonic and tonic seizures, the duration of the seizure period, and the lifetime of the animals before death were evaluated and calculated.
Conclusions. The results obtained are promising for further design of potential anticonvulsants among oxazole-bearing 4-thiazolidones with the possible mechanism of the anticonvulsant action through the GABA-ergic impact and inhibition of the prostaglandin and leukotriene synthesis.

Supporting Agency

  • The research leading to these results has been carried out at the expense of the State Budget of Ukraine and has received funding from the Ministry of Health of Ukraine, under the project numbers: 0121U100690 and 0120U102460.


Download data is not yet available.


  1. Sevim, D.; Karakurt, A. Recent progress in anticonvulsant drug research: strategies for anticonvulsant drug development and applications of antiepileptic drugs for non-epileptic central nervous system disorders. Top. Med. Chem. 2012, 12 (9), 1033-1071.
  2. Löscher, W.; Potschka, H.; Sisodiya, S. M.; Vezzani, A. Drug Resistance in Epilepsy: Clinical Impact, Potential Mechanisms, and New Innovative Treatment Options. Rev. 2020, 72 (3), 606-638.
  3. Löscher, W. Single-Target Versus Multi-Target Drugs Versus Combinations of Drugs with Multiple Targets: Preclinical and Clinical Evidence for the Treatment or Prevention of Epilepsy. Front Pharmacol 2021, 12,
  4. Ciccone, L.; Cerri, C.; Nencetti, S.; Orlandini, E. Carbonic Anhydrase Inhibitors and Epilepsy: State of the Art and Future Perspectives. Molecules 2021, 26 (21), 6380.
  5. Grover, G.; Nath, R.; Bhatia, R.; Akhtar, M. J. Synthetic and therapeutic perspectives of nitrogen containing heterocycles as anti-convulsants. Med. Chem. 2020, 28 (15), 115585.
  6. Ali, R.; Khan, M. A.; Siddiqui, N. Past, Present and Future of Antiepileptic Drug Therapy – Finding a Place for Heterocyclics. Mini-Rev. Med. Chem. 2015, 15 (12), 1024-1050.
  7. Song, M.-X.; Deng, X.-Q. Recent developments on triazole nucleus in anticonvulsant compounds: a review. Enzyme Inhib. Med. Chem. 2018, 33 (1), 453-478.
  8. Wei, C.-X.; Bian, M.; Gong, G.-H. Current Research on Antiepileptic Compounds. Molecules 2015, 20 (11), 20741-20776.
  9. Mishchenko, M.; Shtrygol’, S.; Lozynskyi, A.; Khomyak, S.; Novikov, V.; Karpenko, O.; Holota, S.; Lesyk, R. Evaluation of Anticonvulsant Activity of Dual COX-2/5-LOX Inhibitor Darbufelon and Its Novel Analogues. Pharm. 2021, 89 (2), 22.
  10. Mishchenko, M. V.; Shtrygol, S. Yu.; Lesyk, R. B.; Lozynskyi, A. V.; Holota, S. M. Screening study of new thiazolidinone derivatives for anticonvulsant activity. Zaporozhye Medical Journal 2020, 22 (6), 840–846. [in Ukrainian].
  11. Mishchenko, M.; Shtrygol, S.; Kaminskyy, D.; Lesyk, R. Thiazole-bearing 4-thiazolidinones as new anticonvulsant agents. Pharm. 2020, 88 (1), 16.
  12. Suemaru, K.; Yoshikawa, M.; Tanaka, A.; Araki, H.; Aso, H.; Watanabe, M. Anticonvulsant effects of acetaminophen in mice: Comparison with the effects of nonsteroidal anti-inflammatory drugs. Epilepsy Res. 2018, 140, 22–28,
  13. Vieira, V.; Glassmann, D.; Marafon, P.; Pereira, P.; Gomez, R.; Coitinho, A.S. Effect of diclofenac sodium on seizures and inflammatory profile induced by kindling seizure model. Epilepsy Res. 2016, 127, 107–113,
  14. Akula, K.K.; Dhir, A.; Kulkarni, S.K. Rofecoxib, a selective cyclooxygenase-2 (COX-2) inhibitor increases pentylenetetrazol seizure threshold in mice: Possible involvement of adenosinergic mechanism. Epilepsy Res. 2008, 78, 60–70,
  15. Zhou, L.; Zhou, L.; Cao, S.L.; Xie, Y.J.; Wang, N.; Shao, C.Y.; Wang, Y.-N.; Zhou, J.-H.; Cowell, J.K.; Shen, Y. Celecoxib ameliorates seizure susceptibility in autosomal dominant lateral temporal epilepsy. Neurosci. 2018, 38 (13), 3346–3357.
  16. Dhir, A.; Naidu, P. S.; Kulkarni, S. K. Effect of naproxen, a non-selective cyclooxygenase inhibitor, on pentylenetetrazol-induced kindling in mice. Exp. Pharmacol. Physiol. 2005, 32 (7), 574–584.
  17. Darvishi, H.; Rezaei, M.; Khodayar, M. J.; Reza Zargar, H.; Dehghani, M. A.; Rajabi Vardanjani, H.; Ghanbari, S. Differential Effects of Meloxicam on Pentylenetetrazole- and Maximal Electroshock-Induced Convulsions in Mice. Jundishapur J. Nat. Pharm. Prod. 2017, 12 (2), e36412.
  18. Ostapiuk, Yu. V.; Obushak, M. D.; Matiychuk, V. S.; Naskrent, M.; Gzella, A. K. A convenient method for the synthesis of 2-[(5-benzyl-1,3-thiazol-2-yl)imino]-1,3-thiazolidin-4-one derivatives. Tetrahedron Lett. 2012, 53 (5), 543–545.
  19. Holota, S.; Komykhov, S.; Sysak, S.; Gzella, A.; Cherkas, A.; Lesyk, R. Synthesis, Characterization and In Vitro Evaluation of Novel 5-Ene-thiazolo [3,2-b][1,2,4] triazole-6(5H)-ones as Possible Anticancer Agents. Molecules 2021, 26 (4), 1162.
  20. Golota, S.; Sydorenko, I.; Surma, R.; Karpenko, O.; Gzella, A.; Lesyk, R. Facile one-pot synthesis of 5-aryl/heterylidene-2-(2-hydroxyethyl- and 3-hydroxypropylamino)-thiazol-4-ones via catalytic aminolysis, Commun., 2017, 47 (11), 1071-1076.
  21. Drug Discovery and Evaluation: Pharmacological Assays, 4th Ed.; Hock, F. J., Ed.; Springer: Cham, 2016.




How to Cite

Sydorenko, I. A.; Mishchenko, M. V.; Shtrygol’, S. Y.; Lozynskyy, A. V.; Soronovych, I. I.; Holota, S. M.; Lesyk, R. B. The Synthesis and the Anticonvulsant Activity Screening of New 5-Substituted 2-Imino-4-Thiazolidinone Derivatives. J. Org. Pharm. Chem. 2022, 20, 12-20.



Original Researches